Anti-Viral Agents Flashcards
Steps in Viral Replication
Attachment Entry Uncoating Synthesis Assembly Release
Prototype of antiviral agents that are phosphorylated intracellularly by a viral kinase that inhibits viral DNA synthesis
Acyclovir
MOA of Acyclovir
Converted into Acyclovir triphospate to inhibit viral DNA polymerase
Requirement for Acyclovir in its initial phosphorylation
Viral kinases
Compare the bioavailability of acyclovir and valacyclovir
Acyclovir is MORE bioavailable than valacyclovir
Drug used against herpes virus and does not have an effect on CMV
Acyclovir
Adverse effects of Acyclovir
Extrapyramidal signs and renal dysfunction secondary to crystalline nephropathy
Drugs that decrease Acyclovir clearance
Probenicid and Cemetidine
Compare the serum levels of acyclovir and valacyclovir
Valacyclovir > Acyclovir
CSF levels of acyclovir and valacyclovir
50%
Treatment of choice for postherpetic neuralgia used for suppression of frequently recurring genital herpes
Valacyclovir
Adverse effect of Valacyclovir
Seizures at high doses and thrombotic thrombocytopenic purpura
Acyclic guanine nucleoside analog fro Varicella and Genital Herpes
Penciclovir
Main clinical use for Famciclovir
HSV 1 and 2
Compare the triphosphate activity of Acyclovir and Penciclovir
Acyclovir > Penciclovir
Compare the intracellular concentration of Acyclovir and Penciclovir
Acyclovir < Penciclovir
Major difference of Famciclovir and Acyclovir
Famciclovir does not cause chain termination due to the presence of a 3-OH group
Most common side effects of topical drugs
burning sensation, itchiness, erythema
Most common side effects of oral drugs
Nausea, vomiting, diarrhea
Major adverse effects of Peniclovir and Famciclovir
Testicular toxicity on repeated doses but does not change sperms
MOA of Docosanol
Inhibits fusion between plasma membrane and the HSV envelope preventing viral entry
MOA of Trifluridine
Irreversible inhibition of thymidylate synthase and DNA synthesis inhibitor
Clinical significance of Trifluridine
Keratoconjunctivitis secondary to HSV 1 and 2
Anti-viral activity of Ganciclovir
Active against all herpesviruses but especially active against CMV
MOA of Ganciclovir
Inhibits viral DNA polymerase and causes chain termination
Clinical indication for Ganciclovir
CMV retinitis, CMV prophylaxis and CMV colitis
Adverse effect of Ganciclovir
Myelosuppression
Drugs that increase ganciclovir levels
Probenecid and Trimethoprim
Drug that increase in level with ganciclovir when used together
Didanosine
Clinical indication for ganciclovir
CMV retinitis and CMV prophylaxis in organ transplants
Iodinated thymidine analog that inhibits viral DNA synthesis at low concetration
Idoxuridine
Clinical indication of Idoxuridine
Herpes infections of the eyes but not for systemic viral infections
Clinical indication of Foscarnet
CMV retinitis and Acyclovir resistant HSV 2 and VZV in AIDS patient
Adverse effects of Foscarnet
Nephrotoxicity and penile ilcerations
MOA of Cidofovir
Potent inhibitor and alternative of viral DNA polymerase
Cidofovir is cross-resistant with:
Ganciclovir
Two active metabolites of Cidofovir
Cidofovir diphosphate
Cidofovir phosphocholine
It has a longer half-life between the 2 metabolites of cidofovir
Cidofovir phosphocholine
Cidofovir is administered with what drug to block active tubular secretion
Probenecid
Adverse effect of Cidofovir
Nephrotoxicity and Fanconi’s anemia
MOA of Fomivirsen
Inhibits CMV replication through sequence-specific and non-specific mechanisms
Anti-viral activity of Rimantadine and Amantadine
3 antigenic subtypes of influenza A (H1N1, H2N2, H3N2) ONLY
Indication for use of amantadine and rimantadine
Prophylaxis and treatment of Influenza A2
Seizure effects of Amantadine and Rimantadine
Amantadine > Rimantadine
Adverse effects of Amantadine and Rimantadine
CNS toxicity due to Dopamine
MOA of Oseltamivir and Zanamivir
Inhibitor of Influenza A and B nueraminidase
Route of Administration of Oseltamivir and Zanamivir
Oseltamivir is ORAL and Zanamivir is INHALATIONAL
MOA of Adefovir Dipivoxil
Competitive inhibition of DNA polymerase causing chain termination of DNA synthesis
Metabolite of Adefovir and its effect
Pivalic acid - causes decrease in carnitine levels
Therapeutic effect of Adefovir
For chronic HBV infections in decompensated liver disease
Adverse effect of Adefovir
Nephrotoxicity; lactic acidosis and hepatic steatosis due to mitochondrial dysfunction
Interferons produced by nearly all cells with its effects
Alpha and Beta IFN; anti-viral and anti-proliferative effect
Interferon restricted to T-Lymphocytes and NK Cells with its effects
Gamma IFN; less anti-viral and more potent immunoregulatory effect
MOA of interferon
Transcription, translation, protein processing, virus maturation inhibition
Interferon for chronic hepatitis C
Interferon alpha 2a
Interferon for chronic hepatitis B and C
Interferon alpha 2b
Adverse effects of interferon
Myelosuppression, flu-like symptoms, alopecia, and abortifacient
Drugs that cause hematologic toxicity with interferon
Zidovudine and Ribavirin
Interferon has increased risk of hepatic failure with:
Didanosine
Interferon has increased risk of BM suppression with:
Zidovudine
Linear or branched PEG moiety attached to IFN used for chronic Hepatitis C
Pegylated interferon
Pharmacokinetics of Lamivudine
Poor CSF penetration and freely crosses the placenta
MOA of Ribavirin
Competitive inhibition of GTP-dependent 5’’ capping causing defective replication
This drug stays for more than 6 months after administration lethal to pregnant women
Ribavirin
Adverse effect of Ribavirin
Systemic hemolytic anemia; contraindicated in pregnancy
Clinical Indication of Palivizuumab
Prophylaxis for RSV
This drug lacks direct anti-viral effect but induces cytokines and chemokines with anti-viral effects
Imiquimod
MOA of imiquimod
Induction of interferons
Drug used as topical for condylomata cuminata and actinic keratosis
Imiquimod
Adverse effect of Imiquimod
Influenza-like syndrome
MOA of immunoglobulins
Inhibits viral penetration, opsonize viral particles, activate complement, stimulate cell-mediated immunity
Viral enzyme that synthesizes DNA using viral RNA as template
Reverse transcriptase
Drugs with high chance of mutation
Abacavir
Lamivudine
Emtricitabine
Targets of Anti-HIV drugs
Virus-cell fusion
Reverse transcription
Proteolytic processing
First line agent drug for pregnant women to prevent vertical transmission of HIV
Zidovudine
Fixed dose combinations used against HIV
Zidovudine and Lamivudine OR
Zidovudine and Lamivudine and Abacavir
This drug increases Zidovudine’s level
Phenytoin
Drugs that increase Zidovudine’s level
Probenecid
Fluconazole
Atovaquone
Valproic acid
Zidovudine is active against
HIV 1&2; HTLV 1&2
Didanosine is active against
HIV 1&2, HTLV 1
Adverse effects of Didanosine
Peripheral neuropathy and dose-dependent pancreatitis
Drugs whose levels decrease when given with Didanosine
Ciprofloxacin
Ketoconazole
Itraconazole
Drugs that increase didanosine levels
Allopurinol
Tenofovir
Drugs that decrease didanosine levels
Methadone
Atanazavir
Delavirdine
Stavudine is active against
HIV 1&2
Adverse effects of Stavudine and Zalcitabine
Dose=related peripheral neuropathy, fat atrophy
This drug has a more anti-retroviral activity in monocyte-macrophage cell lines
Zalcitabine
Drugs which increase zalcitabine levels
Probenecid
Cimetidine
Lamivudine and Tenofovir are active against
HIV 1&2; HBV
This drug counteracts phosphorylation of Zalcitabine
Lamivudine
Drugs for pregnant women
Lamivudine
Zidovudine
Atazanavir
Adverse effect of Abacavir
Fatal hypersensitivity syndrome (fever, abdominal pain, GI complaints)
Anti-HIV pre-exposure prophylaxis
Tenofovir and Emtricitabine
Oral solution of this drug contains propylene glycol contraindicated in young children, women, and patients with renal and hepatic failure
Emtricitabine
Adverse effect of Emtricitabine
Hyperpigmentation of skin
Anti-viral activity of NNRTI
HIV 1 but not HIV 2 and no activity on DNA polymerases
MOA of NNRTI
Inhibits viral reverse transcriptase and does not require phosphorylation
Adverse effects of Nevirapine
Dose-limiting toxicity: rash on trunk, face and extremities (SPARES PALMS AND SOLES)
NNRTI drug that has reduced efficacy with antacids, PPIs, and H2 blockers
Delavirdine
Dihydrobenzoxazinone NNRTI
Efavirenz
Bisheteroarylpiperazine NNRTI
Delavirdine
Dipyridodiazepinone NNRTI
Nevirapine
Adverse effect of Efavirenz
CNS toxicity
Adverse effect of Delavirdine
Skin rash (teratogenic)
MOA of protease inhibitors
Prevent proteolytic cleavage of HIV polyproteins and prevents metamorphosis of HIV virus particles into its adult form
Protease inhibitor with least potency to inhibit CYP3A4
Saquinavir
Adverse effect of saquinavir
Prolonged QT interval
Protease inhibitor with most potency to inhibit CYP3A4
Ritonavir
Adverse effect of Ritonavir
GI toxicity and dose-dependent hyperTG and hypercholesterolemia
Adverse effect of indinavir
nephrolithiasis and HIV lipodystrophy syndrome
Non-peptidic protease inhibitor
Nelfinavir
Nelfinavir has increased dose when given with
Rifabutin
Only protease inhibitor with a sulfonamide moiety
Amprenavir
Protease inhibitor with greatly increased water solubility and improved oral bioavailability
Fosamprenavir
This drug is a weak CYP3A4 inhibitor but becomes strong with Ritonavir
Lopinavir
Azapeptide protease inhibitor contraindicated in patients with hepatic insufficiency and is recommended in pregnant patients
Atazanavir
Relatively new protease inhibitor with increased risk of intracranial hemorrhage
Tipranavir
The only available HIV entry inhibitor
Enfuvirtide
Entry inhibitor accumulated in the cervicovaginal fluid
Maraviroc
Entry inhibitor accumulated in seminal fluid
Atanovir
MOA of Enfuvirtide
Binds to gp41 subunit of glycoprotein preventing conformational changes for fusion of viral and cellular membranes